Apr 27 |
Public companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last week
|
Apr 13 |
Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time
|
Mar 28 |
Gyre Therapeutics Inc (GYRE) Announces Full Year 2023 Financial Outcomes and Business Progress
|
Mar 26 |
Gyre Therapeutics GAAP EPS of -$1.41, revenue of $113.5M
|
Mar 26 |
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
|
Mar 21 |
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
|
Feb 29 |
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Feb 23 |
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
|
Jan 9 |
Gyre Therapeutics: Little Known Liver Disease Company, But Nothing Stands Out
|
Dec 15 |
Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding
|